Skip to main content

Advertisement

SpringerLink
Log in

When biotech goes bad

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

An Erratum to this article was published on 09 June 2016

This article has been updated

A look at 20 years of the dark side of biotech.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Change history

  • 31 March 2016

    In the version of this article initially published, on p.286, in the timeline, far right, “2008 Intercept” should have read “2008 InterMune.” The error has been corrected in the HTML and PDF versions of the article.

Author information

Authors and Affiliations

  1. John Hodgson is Data Editor, Pharma at Informa Business Information, London, UK, and Editor-at-Large, Nature Biotechnology.,

    John Hodgson

Authors
  1. John Hodgson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Hodgson.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hodgson, J. When biotech goes bad. Nat Biotechnol 34, 284–291 (2016). https://doi.org/10.1038/nbt.3510

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3510

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation